Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.54 USD | +0.71% | -3.44% | -28.05% |
04-09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
04-03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.05% | 2.2B | |
-2.93% | 103B | |
+1.36% | 95.28B | |
+1.46% | 22.15B | |
-16.05% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.25% | 16.05B | |
+4.87% | 13.68B | |
+33.03% | 12.17B |
- Stock Market
- Equities
- DNLI Stock
- News Denali Therapeutics Inc.
- Denali Therapeutics : Reports Phase 1 Results For Studies Targeting Amyotrophic Lateral Sclerosis -- Shares Rise After-Hours